Accession Number : AD1013500


Title :   A New Paradigm for the Treatment of Ovarian Cancer: The Use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy


Descriptive Note : Technical Report,30 Sep 2014,29 Sep 2015


Corporate Author : The Johns Hopkins University Baltimore United States


Personal Author(s) : Baylin,Stephen B


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1013500.pdf


Report Date : 01 Oct 2015


Pagination or Media Count : 67


Abstract : The overall goal of this project remains to bring epigenetic therapy strategies to have major impact forthe management of advanced ovarian cancer (OC). In the first year, we have made exciting advances for this purpose and especially for the concept of utilizing low dose epigenetic therapy to target DNA demethylation and histone deacetylase inhibition (HDACi) to maximize responses to immune checkpoint therapy. We identified, from studies of multiple OC cell lines how low doses of the DNA demethylation agents, azacytidine (AZA) and deoxy-azacytidine (DAC) induce a deep immune attraction signature.


Descriptors :   Ovarian cancer , therapeutics


Distribution Statement : APPROVED FOR PUBLIC RELEASE